{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:25:33Z","timestamp":1772166333679,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021080","name":"Creutzfeldt-Jakob Disease Foundation","doi-asserted-by":"publisher","award":["Creutzfeldt-Jakob Disease Foundation"],"award-info":[{"award-number":["Creutzfeldt-Jakob Disease Foundation"]}],"id":[{"id":"10.13039\/100021080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Creutzfeldt\u2013Jakob disease (CJD) is a severe neurodegenerative disorder characterized by the abnormal accumulation of prion proteins. In Israel, a unique epidemiological pattern of CJD has been identified, specifically a genetic form (gCJD) associated with the E200K mutation in the PRNP gene. Investigating rare diseases such as CJD syndrome poses challenges due to their low prevalence, hindering the formation of an adequate patient cohort for comprehensive research and treatment trials. To overcome this limitation, biobanks have emerged as transformative tools for collecting and distributing biological specimens along with corresponding health data. Biobanks offer a solution to the inherent heterogeneity in rare diseases, allowing researchers to access diverse and extensive sample sets, thereby enhancing the understanding of disease nuances toward potential therapy. We introduce a novel collaborative model involving the Negev BioBank (NBB), the Creutzfeldt\u2013Jakob Israel Foundation, the Israeli National BioBank for Research (MIDGAM), and the Israeli Ministry of Health. Each entity contributes unique expertise and resources to establish a comprehensive platform for studying the disease. The goal was to establish a participant pool of 500 individuals, including clinically diagnosed cases, confirmed carriers of the E200K mutation, and their first- and second-degree relatives. During the pilot phase of the last year, 250 participants were enrolled, with each family contributing between 1 and 25 participants. This collaborative approach involving communities, scientists, physicians, and regulatory bodies establishes a model applicable across various fields. These synergistic efforts aim to advance research on CJD and potentially serve as a blueprint for studying other rare diseases.<\/jats:p>","DOI":"10.1186\/s13023-025-03703-6","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:43:02Z","timestamp":1744263782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["National Creutzfeldt\u2013Jakob disease research biobank, a novel approach to the establishment of the scientific platform: collaboration between patient advocacy group, scientists, regulators and physicians"],"prefix":"10.1186","volume":"20","author":[{"given":"Alice","family":"Anane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doron","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon A.","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8706-9622","authenticated-orcid":false,"given":"Victor","family":"Novack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"3703_CR1","doi-asserted-by":"crossref","unstructured":"Appleby BS, Shetty S, Elkasaby M. Genetic aspects of human prion diseases. Front Neurol. 2022;13.","DOI":"10.3389\/fneur.2022.1003056"},{"issue":"9","key":"3703_CR2","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000160117.56690.B2","volume":"64","author":"A Ladogana","year":"2005","unstructured":"Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64(9):1586\u201391.","journal-title":"Neurology"},{"issue":"1","key":"3703_CR3","first-page":"31","volume":"46","author":"E Mitrov\u00e1","year":"2002","unstructured":"Mitrov\u00e1 E, Belay G. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. Acta Virol. 2002;46(1):31\u20139.","journal-title":"Acta Virol"},{"issue":"1","key":"3703_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13195-021-00912-6","volume":"13","author":"T Ximelis","year":"2021","unstructured":"Ximelis T, Mar\u00edn-Moreno A, Espinosa JC, Era\u00f1a H, Charco JM, Hern\u00e1ndez I, et al. Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. Alzheimers Res Ther. 2021;13(1):176.","journal-title":"Alzheimers Res Ther"},{"key":"3703_CR5","unstructured":"Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8(322)."},{"issue":"9","key":"3703_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.41.9.1385","volume":"41","author":"N Zilber","year":"1991","unstructured":"Zilber N, Kahana E, Abraham M. The Libyan Creutzfeldt-Jakob disease focus in Israel: an epidemiologic evaluation. Neurology. 1991;41(9):1385\u20131385.","journal-title":"Neurology"},{"issue":"9145","key":"3703_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(05)61335-9","volume":"352","author":"M D\u2019Alessandro","year":"1998","unstructured":"D\u2019Alessandro M, Petraroli R, Ladogana A, Pocchiari M. High incidence of Creutzfeldt-Jakob disease in rural Calabria, Italy. Lancet. 1998;352(9145):1989\u201390.","journal-title":"Lancet"},{"issue":"5","key":"3703_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/BF00143120","volume":"7","author":"E Mitrov\u00e1","year":"1991","unstructured":"Mitrov\u00e1 E, Bronis M. Clusters of CJD in Slovakia: the first statistically significant temporo-spatial accumulations of rural cases. Eur J Epidemiol. 1991;7(5):450\u20136.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"3703_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","volume":"19","author":"E Tambuyzer","year":"2020","unstructured":"Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov. 2020;19(2):93\u2013111.","journal-title":"Nat Rev Drug Discov"},{"key":"3703_CR10","unstructured":"EURORDIS. The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe. 2009."},{"key":"3703_CR11","doi-asserted-by":"crossref","unstructured":"Minikel EV, Vallabh SM, Orseth MC, Brandel JP, Ha\u00efk S, Laplanche JL et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology. 2019;93(2).","DOI":"10.1212\/WNL.0000000000007745"},{"issue":"3","key":"3703_CR12","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"issue":"7","key":"3703_CR13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"JC Denny","year":"2019","unstructured":"Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, et al. The all of Us research program. N Engl J Med. 2019;381(7):668\u201376.","journal-title":"N Engl J Med"},{"key":"3703_CR14","doi-asserted-by":"crossref","unstructured":"Gainotti S, Torreri P, Wang CM, Reihs R, Mueller H, Heslop E, et al. The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. European Journal of Human Genetics. 2018;26(5):631\u201343.","DOI":"10.1038\/s41431-017-0085-z"},{"key":"3703_CR15","unstructured":"Global Genes. About us: Our mission and vision [Internet]. Global Genes. 2023 [Cited 2025 Feb 17]. Available from: http:\/\/globalgenes.org\/about-us\/"},{"key":"3703_CR16","unstructured":"Progeria Research Foundation Cell &. Tissue Bank [Internet]. [cited 2025 Feb 17]. Available from: https:\/\/www.progeriaresearch.org\/cell-and-tissue-bank\/"},{"key":"3703_CR17","unstructured":"Friedreich\u2019s Ataxia Research Alliance Biobank [Internet]. [cited 2025 Feb 17]. Available from: https:\/\/www.curefa.org\/biobank"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03703-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03703-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T18:03:30Z","timestamp":1744308210000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03703-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03703-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4504784\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CJD Biobank was approved by the Soroka University Medical Center Ethics Committee: (Approval No: SOR-0137-18). All participants provided their informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alice Anane serves as chairperson of the Creutzfeldt\u2013Jakob Israel Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}